NEWS HIGHLIGHTS
Published Studies Related to Combigan (Brimonidine / Timolol Ophthalmic)
An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. [2008.12]
PURPOSE: To compare the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure (IOP) over 8 weeks... CONCLUSIONS: Both fixed combinations were capable of significantly reducing the mean diurnal IOP, mean diurnal peak, and mean WDT peak after 8 weeks of treatment. Also, both fixed combinations are well tolerated with few side effects.
12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. [2005.09]
PURPOSE: To evaluate the efficacy and safety of fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID and demonstrate non-inferiority to concomitant use of brimonidine tartrate 0.2% BID and timolol 0.5% BID in glaucoma and ocular hypertension patients with intraocular pressure (IOP) uncontrolled on monotherapy... CONCLUSIONS: Brimonidine/timolol fixed-combination therapy is as safe and effective as concomitant treatment with the individual components. Its simplified dosing regimen has the potential to improve compliance.
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. [2005.08]
PURPOSE: The aim of this study was to compare the safety and intraocular pressure (IOP)- lowering efficacy of a fixed combination of brimonidine 0.2% and timolol 0.5% (fixed brimonidine/ timolol) versus each drug used as monotherapy... CONCLUSIONS: The fixed combination of brimonidine and timolol was well-tolerated and provided significantly better IOP control compared with either brimonidine or timolol used alone.
Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. [2009.04]
OBJECTIVE: At the introduction of the fixed-combination of brimonidine/timolol in Germany in 2006, a non-interventional, multicenter, observational, open-label study was initiated to evaluate efficacy, tolerability, and safety of this preparation in a broad patient population... CONCLUSIONS: Although this study was limited by its observational design, our results show that the fixed combination of brimonidine 0.2%/timolol 0.5% was effective, well tolerated, and safe in a broad POAG patient population.
Efficacy, safety, and current applications of brimonidine. [2008.11]
CONCLUSION: Brimonidine is an important component of topical glaucoma treatment that is most limited by local ocular intolerance.
Clinical Trials Related to Combigan (Brimonidine / Timolol Ophthalmic)
A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt [Recruiting]
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension [Recruiting]
Glaucoma is one of the most common causes of blindness in the industrialized nations. For a
long time glaucoma has been defined as a disease in which high intraocular pressure (IOP)
leads to irreversible optic disc damage and subsequent visual field loss. However, recent
investigations show that IOP is not the only factor that is involved in the glaucomatous
process leading to retinal ganglion cell death. The role of vascular factors in the
pathogenesis of glaucoma has recently received much attention based on animal experiments
and epidemiological studies. The main focus of glaucoma is still directed towards a decrease
in IOP. There is, however, also considerable interest whether antiglaucoma drugs influence
ocular perfusion. Although measurement of ocular blood flow is still difficult, a number of
innovative techniques have been realized which cover different aspects of ocular perfusion.
In the present study Xalacom® (latanoprost/timolol) and the fixed combination of Combigan®
(brimonidine/timolol) will be compared with respect to their IOP lowering efficacy as well
as their ocular hemodynamic effects.
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects [Recruiting]
Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive
therapy to Xalatan in subjects with glaucoma or ocular hypertension.
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG) [Recruiting]
We have completed a study in which we examined the response of the retinal circulation to
changes in posture from sitting to lying down in patients with primary open angle glaucoma
(POAG). This alteration in position produces changes in the local blood pressure at the
entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by
dilating and constricting in order to maintain a steady blood flow rate. In an eye with
POAG, this often does not occur. As a result, there are large fluctuations in blood flow
which may produce the retinal neuronal damage associated with glaucoma.
The purpose of this study is to demonstrate that topical anti-glaucoma treatments with
agents that have vasoactive as well as IOP-lowering effects can have a beneficial effect on
maintaining a steady retinal blood flow rate even when there are changes in local blood
pressure.
Ciracadian Ocular Perfusion and Ocular Blood Flow [Recruiting]
Compare the short term effects of two IOP-lowering medications on ocular perfusion pressure,
ocular blood flow, circadian IOP and blood pressure in patients with glaucoma.
|
